Prilenia Therapeutics
PrivateLast Round
Series B
Apr 12, 2022
Total Funding Raised
$180.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Prilenia Therapeutics is a biotechnology company that develops novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, including Huntington's disease and amyotrophic lateral sclerosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prilenia Therapeutics Comparables
Compare Prilenia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QurAlis | 81% | |
| Neurizon Therapeutics Limited | 80% | |
| NeuroSense Therapeutics | 78% |
Prilenia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 12, 2022 | ||||
| Series B | Nov 3, 2021 | ||||
| Series A | Jun 3, 2020 | ||||
| Seed | Sep 1, 2018 |
Key People
Founding team and executive leadership
Prilenia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series B |
| Forbion | Series B, Series A |
| Amplitude Ventures | Series B |
| Morningside Ventures | Series B, Series A |
| Genworks Health | Series A |
| ALS Investment Fund | Series B |
| Sectoral | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 1, 2026
Lead candidate pridopidine granted designation in U.S. and EU for HD and ALS.
- May 1, 2026
Job posting references Ferrer's QA team for clinical trial oversight.
Recent news
Latest coverage and updates
- hiresSep 8, 2026
Prilenia hired Munschauer as chief medical officer on Sep 8th '26.
- hiresSep 8, 2026
Prilenia hired Frederick (Rick) E. Munschauer III as Chief Medical Officer on Sep 8th '26.
Prilenia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Prilenia Therapeutics's valuation, stock price, and market status.
Is Prilenia a public or private company?
Prilenia is a private company.
What is the current stock price of Prilenia?
Prilenia is a private company with no public stock price. No recent secondary market data is available.
How much is Prilenia worth (valuation)?
Valuation information for Prilenia is not publicly available.
Can I buy Prilenia stock?
Prilenia shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Prilenia's last funding round?
Prilenia's most recent funding round was Series B Extension on April 12, 2022.
Who are the main investors in Prilenia?
Key investors in Prilenia include SV Health Investors, Amplitude Ventures, Morningside Ventures, Genworks Health, ALS Investment Fund.
Will Prilenia IPO soon?
No public IPO plans have been announced for Prilenia.
How can I track Prilenia secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Prilenia's secondary market activity and sign up for updates.